May 8, 2007 - OBS Medical and Physio-Control Inc., a wholly-owned subsidiary of Medtronic Inc., announced they have entered into a strategic relationship to improve patient safety through medical information innovations in external defibrillation monitoring technologies.

Arrow’s Transradial introducers provide for durable radial artery access while being vessel friendly. Our newest kit contains our .018 micro-puncture wire guide and needle set to minimize vessel trauma. The 6 French sheath and dilator track well over the smaller wire and we’ve applied a hydrophilic coating on the polyurethane sheath to enhance insertion and removal.

May 7, 2007 — Citing issues related to potentially suboptimal therapeutic dosing of paclitaxel, Conor Medsystems, LLC, has concluded that the COSTAR II (CObalt Chromium STent with Antiproliferative for Restenosis) trial, the pivotal study for the CoStar(R) cobalt chromium paclitaxel-eluting coronary stent, failed to meet its primary endpoint. The trial did not identify safety issues, and the overall rates of death, myocardial infarction and stent thrombosis were consistent with those observed in other clinically relevant drug-eluting stent studies.

May 7, 2007 — Thoratec Corp., a global maker of products to treat cardiovascular disease, says the FDA has approved an IDE (Investigational Device Exemption) supplement that allows enrollment of up to an additional 60 patients in the Bridge-to-Transplantation (BTT) arm of the company's HeartMate II Phase II trial under a Continued Access Protocol (CAP).

This is the third CAP the company has received for this trial, and the company recently received CAP approval for the Destination Therapy (DT) arm of the trial.

May 7, 2007 Stereotaxis Inc. announced today that it has developed an innovative new single-screen user interface that provides an unprecedented level of interventional lab integration. The product, Odyssey, is a proprietary Stereotaxis design that consolidates multiple information sources and screens within an electrophysiology interventional lab into a single visual display.

May 7, 2007 — Australia's adult stem cell company, Mesoblast Limited, has announced that the FDA has cleared the Investigational New Drug Submission (IND) of its U.S.-based sister company, Angioblast Systems Inc., to commence a Phase 2 clinical trial of its allogeneic, or 'off-the-shelf,’ adult stem cells for patients with heart attacks.

May 7, 2007 — Signalife Inc. has announced that it has submitted its Fidelity 200 Cardiac Event Recorder 510K pre-market notification to the FDA. Upon clearance the recorder will be sold over-the-counter.

Utilizing its proprietary signal processing technology and amplification process, Signalife says the exceptional signal clarity of the device will allow it to become a new standard in cardiac event recording.

May 7, 2007 — Hansen Medical Inc. has announced it has obtained FDA clearance for commercialization of the Sensei Robotic Catheter System and Artisan Control Catheter to facilitate manipulation, positioning and control of mapping catheters during electrophysiology (EP) procedures.

May 7, 2007 — Steven E. Nissen, M.D., chairman of the Department of Cardiovascular Medicine at Cleveland Clinic, and immediate past president of the American College of Cardiology, has been named one of the 100 Most Influential People by Time magazine. He will be featured among other "Scientists and Thinkers."

May 7, 2007 — Ortho-Clinical Diagnostics Inc. has initiated a voluntary, nationwide recall of two lots of a diagnostic test used by physicians to aid in the diagnosis of injury to heart muscle and/or heart attack because of shifts in test results that could contribute to a missed diagnosis of myocardial infarction.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now